Improving the cost-effectiveness of a healthcare system for depressive disorders by implementing telemedicine: a Health Economic Modeling Study. by Lokkerbol, J. et al.
Improving the Cost-Effectiveness of
a Healthcare System for Depressive
Disorders by Implementing Telemedicine:
A Health Economic Modeling StudyJoran Lokkerbol, M.Sc., Dirk Adema, M.Sc., Pim Cuijpers, Ph.D.,
Charles F. Reynolds III, M.D., Richard Schulz, Ph.D., Rifka Weehuizen, Ph.D.,
Filip Smit, Ph.D.Received Novem
Mental Health
Amsterdam, The
University of P
Epidemiology a
The Netherlands
The Netherlands
 2013 Ame
http://dx.d
Am J Geriatr PsObjectives: Depressive disorders are signiﬁcant causes of disease burden and are
associated with substantial economic costs. It is therefore important to design
a healthcare system that can effectively manage depression at sustainable costs. This
article computes the beneﬁt-to-cost ratio of the current Dutch healthcare system for
depression, and investigates whether offering more online preventive interventions
improves the cost-effectiveness overall. Methods: A health economic (Markov) model
was used to synthesize clinical and economic evidence and to compute population-level
costs and effects of interventions. The model compared a base case scenario without
preventive telemedicine and alternative scenarios with preventive telemedicine. The
central outcome was the beneﬁt-to-cost ratio, also known as return-on-investment
(ROI). Results: In terms of ROI, a healthcare system with preventive telemedicine for
depressive disorders offers better value for money than a healthcare system without
Internet-based prevention. Overall, the ROI increases from V1.45 ($1.72) in the base
case scenario to V1.76 ($2.09) in the alternative scenario in which preventive tele-
medicine is offered. In a scenario in which the costs of offering preventive telemedicine
are balanced by reducing the expenditures for curative interventions, ROI increases to
V1.77 ($2.10), while keeping the healthcare budget constant. Conclusions: For
a healthcare system for depressive disorders to remain economically sustainable, its
cost-beneﬁt ratio needs to be improved. Offering preventive telemedicine at a large scale
is likely to introduce such an improvement. (Am J Geriatr Psychiatry 2013; -:-e-)
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Implementing Telemedicineepression is the single leading cause of nonfatal
1e3Ddisease burden and has substantial economic
consequences.4e7 Reducing the disease burden due to
depressive disorders at affordable costs is therefore of
great signiﬁcance to public health.
Cushioning the adverse effects of depression
requires a healthcare systemwell equipped tomanage
the disorder. To that end, the interventions for de-
pression that are offered need to be acceptable to both
healthcare users and healthcare providers. In addition,
the interventions must be effective in generating the
required health gains and be economically sustainable
over time. It is difﬁcult to identify which particular
combination of interventions will meet all these
criteria within the extensive range of available options
that are offered in multiple formats to different target
groups.
The task of identifying an “optimal” healthcare
system becomes even more daunting when the acc-
eptability and cost-effectiveness of a newly designed
healthcare system have to be compared with the
cost-effectiveness of the current healthcare system. In
particular, we need to know how a (hypothetical)
healthcare system based on widespread implementa-
tion of preventive telemedicine would compare with
the current healthcare regimen without preventive
telemedicine. Would such a healthcare system
produce larger health gains? In addition, how would
the new system compare with the current healthcare
regimen in terms of its beneﬁt-to-cost ratio?
To facilitate decisionmaking,we developed a health
economic simulation model for depression called
DEPMOD. This model assesses the population-level
cost-beneﬁt ratio of an alternative healthcare system
relative to the current one. Although availability of
data prompted us to apply DEPMOD to the pop-
ulation aged 18e65 years, we expect that DEPMOD is
also relevant to older populations. This is especially
true because the older population has an elevated risk
for depression,8 and the evidence suggests an in-
creased risk of additional adverse outcomes for older
people with depression.9 The older population might
be under pressure to be economically productive, even
beyond the current age of retirement, due to the
present-day economic downturn in “graying” socie-
ties. At the same time, increased life expectancy,
common in high-income countries, is associated with
an increase in the number of depressed older people.2In sum, graying societies, increased demand for
mental healthcare, rising healthcare expenditure, and
dwindling labor forces for mental health underscore
the importance of the healthcare system being reas-
sessed and geared toward offering more cost-effective
interventions. Implementing interventions that can be
offered over the Internet seems to be a promising
approach because these interventions are likely to
be scalable, effective, and cost-effective. DEPMOD
simulates the possible consequences of offering Int-
ernet interventions for major depression.
Experience with the Australian Assessing Cost-
Effectiveness models for heart disease, mental disor-
ders, and prevention10e12 and the WHO-CHOICE
models (Choosing Interventions That Are Cost-
Effective)13,14 indicates that health economic models
may have value for policy making. DEPMOD was
speciﬁcally designed for the Dutch healthcare system,
using Dutch population-based cohort data on
depressive disorder15 and standard cost prices perti-
nent to the Dutch healthcare system.16 It also models
the impact of several preventive e-health interventions
that were recently developed, evaluated, and
disseminated in The Netherlands. However, DEP-
MOD can be used for other countries and populations,
provided that data requirements are met.
The aim of the current article was to brieﬂy describe
DEPMOD and then apply DEPMOD by modeling the
current package of healthcare interventions and an
extended package in which preventive telemedicine is
added. The goalwas to address the question ofwhether
preventive telemedicine offers good value for money.
We deﬁne telemedicine (e-health) as psychological
self-help interventions that are delivered over the
Internet, either with or without minimal therapist
support. Meta-analyses of randomized trials have
demonstrated the effectiveness of both prevention of
depressive disorder17,18 and (preventive) e-health
interventions.19,20 In addition, telemedicine is very
scalable because of the widespread usage of the
Internet. It should be noted that older people are the
fastest growing group of new Internet users, and one
of the main reasons older individuals use the Internet
is because they are seeking answers to health ques-
tions. By implication, there is a good match between
older people’s Internet usage and e-mental health.
Although not explicitly modeled here, evidence
suggests that depression prevention is also effective inAm J Geriatr Psychiatry -:-, - 2013
Lokkerbol et al.the older population.21 The goal of the current article
was to synthesize the relevant clinical and economic
evidence in a health economic modeling study.METHODS
Comparing Scenarios: Usual Care Versus More
Preventive Telemedicine
DEPMOD is used to compute the cost-beneﬁt ratio
by comparing “usual care”with an alternative scenario
in which usual care is augmented with preventive
telemedicine (Scenario A). In addition, Scenario B is
analyzed in which the costs of offering additional
preventive telemedicine are compensated for by red-
ucing the healthcare budget for curative interventions,
thereby keeping the overall costs of the new scenario
under the current budgetary ceiling.
The usual care scenariowhich forms the basis for the
comparisons is an evidence-based healthcare system
that is fully in agreement with the Dutch clinical
guidelines for the treatment of depression. Because it
is likely to be better than the current Dutch healthcare
system, we refer to it as “enhanced usual care”
(Table 1). This long list of evidence-based interven-
tions was then used to select only those interventions
thatwere acceptable from apatient’s point of view and
were appropriate from a healthcare professional’s
point of view. To that end, focus groups were used;
a panel of 17 healthcare users judged to what extent
theywould be willing to accept and actively engage in
each of the interventions, whereas a panel of 10 hea-
lthcare professionals judged to what extent the inter-
ventions were appropriate to offer for the various
manifestations of depressive disorder. Both panels
showed a relatively high degree of consensus with
regard to their preferences (Cronbach alpha¼ 0.79 for
care users and 0.70 for care providers). Taking these
preferences into account, the extensive evidence-
based interventions was reduced to a shorter list of
interventions that are not only evidence based but also
preference based (Table 1).17,19,22e33
The list of evidence-based and preference-based
interventions forms the basis for performing scenario
analysis and is likely to be more cost-effective than
usual care. In usual care, not every intervention is
evidence based or meets with approval by both care
users and healthcare providers.Am J Geriatr Psychiatry -:-, - 2013Table 2 describes the scenarios that were analyzed
by using DEPMOD. First, the base case scenario of
evidence-based and preference-based care without
prevention was assessed, in which coverage rates
and adherence rates were elicited from the focus
groups. The alternative scenario (Scenario A) is
essentially the same as the base case scenario, except
prevention and (preventive) telemedicine is now
offered. To be more speciﬁc, prevention consists of
face-to-face interventions with an arbitrarily low
coverage rate set at 2%. Preventive e-health inter-
ventions are offered at a coverage rate of 15%, which
is likely to be attainable in practice.34 E-health inter-
ventions for prevention of relapse and recurrence are
assumed to be somewhat lower, with coverage set at
10%. Finally, Scenario B offers telemedicine as in
Scenario A, while cutting back on other treatment
costs, thus keeping the overall costs balanced.
Coverage rates in both alternative scenarios are
hypothetical and can be used to conduct “what-if”
analyses around potentially interesting healthcare
systems.
The remainder of the Methods section describes
DEPMOD, which is based on methods as described
by Briggs et al.35 and Drummond et al.36DEPMOD
Conceptually, DEPMOD combines the epidemi-
ology of major depression and simulates how a hea-
lthcare system affects the incidence (via prevention),
prevalence (via treatment), and recurrence (via relapse
prevention) of the disorder. Generating health impacts
by offering interventions entails costs. Both the costs
and the health gains are evaluated by using DEPMOD.
The epidemiology of depression ismodeled as a series
of transitions between different health states (healthy,
depressed, and death), taking into account both severity
of depression (subclinical, mild, moderate, and severe
depression) and the number of depressive episodes
(recurrences). The simulated healthcare system consists
of a mix of preventive interventions, curative interven-
tions (for mild, moderate, and severe depression), and
interventions to prevent recurrences, as outlined in
Tables 1 and 2.
The purpose of DEPMOD is to calculate the total
healthcare expenditure and health gains under the
current healthcare system, and to compare the
current scenario with the alternative scenarios. The3
TABLE 1. Selected Evidence-Based and Preference-Based Interventions According to Depression Severity Level
Costs Compliance Rate Effect
V ($) % OR
Subclinical depression
Self-help booka 348 (413) 52 0.66
Group course: 8e10 sessionsb 506 (601) 64 0.57
E-health intervention (unsupported)c 178 (211) 56 0.55
V ($) % d
Mild depression
E-health intervention (supported)c 313 (372) 43 0.32
Interapy: online psychotherapy, 10 sessions of CBTd 2,154 (2,558) 44 0.70
Individual psychotherapy, primary care, 8 sessionse 1,296 (1,539) 56 0.69
Moderate depression
E-health intervention (supported)c 313 (372) 43 0.32
Interapy: online psychotherapy, 14 sessions of CBTf 2,154 (2,558) 44 0.70
Individual psychotherapy, primary care, 8 sessionse 1,296 (1,539) 56 0.69
Severe depression
Individual psychotherapy, outpatient care, 8e24 sessionsg 1,447 (1,719) 68 0.70
Antidepressants, 3e6 months via GPh 235 (279) 44 0.72
Antidepressants, 3e6 months, with additional psychological supporti 289 (343) 56 0.72
Combination therapy (medication and psychotherapy)j 1,215 (1,443) 65 1.05
V ($) % OR
Recurrent depression
Clinical management with maintenance medication, 12 monthsk 537 (638) 42 0.75
Preventive cognitive therapy: 8 group sessionsk 406 (482) 63 0.73
Supported self-help PCT: via the Internetl 403 (479) 46 0.73
Notes: Data are given as costs (in 2009 euros and dollars), compliance with therapy (%), and effect, as odds ratio (OR) or as standardized
effect size, d, all representing average values. GP: general practitioner; PCT: preventive cognitive therapy.
aTaken from Willemse et al.22
bTaken from Cuijpers et al.17,23
cTaken from Spek et al.19 and Cuijpers et al.24
dTaken from Ruwaard et al.25
eTaken from Cuijpers et al.26,27
fTaken from Ruwaard et al.25
gTaken from Ekers et al.28
hTaken from Arroll et al.,29 Fournier et al.,30 and Kirsch et al.31
iTaken from Fournier et al.30 and Kirsch et al.31
jTaken from Cuijpers et al.32
kOur reanalysis of the meta-analysis by Vittengl et al.33
lSee k. Hypothetical effect size on the assumption that supported e-health is as effective as face-to-face delivered prevention of recurrence,
albeit associated with a lower adherence rate.
Implementing Telemedicinefollowing sections describe the model, the data, and
the underlying assumptions in more detail.
Epidemiology. DEPMOD is restricted to depressive
disorder, as deﬁned according to the Diagnostic and
Statistical Manual of Mental Disorders, Third Edition.37
DEPMOD assumes a population of 10 million people,
aged 18e65 years. Estimates of incidence (238,350 new
cases per year), episode duration (6 months on
average), prevalence (588,600 acute cases annually),
and recurrence rates of depressive disorder (45% of the
currently depressed people have a history of previous
episodes) were obtained from The Netherlands4Mental Health Survey and Incidence Study, a
population-based psychiatric epidemiologic cohort
study.15 Depression-speciﬁc mortality rates were
assessed by using a meta-analytic approach.38 DEP-
MOD takes into account that the risk of yet another
depressive episode increases with the number of
previous episodes.
Healthcare system. A healthcare system consists of
preventive interventions to reduce incidence; treatment
of mild, moderate, and severe depression to reduce
disease burden; and relapse prevention in recovered
patients to reduce risk of relapse and recurrence. TheseAm J Geriatr Psychiatry -:-, - 2013
TABLE 2. Modeled Scenarios: Coverage Rates (%) for Each of the Interventions According to Depression Severity Level
Base Case Alternative A Alternative B
Subclinical depression
Self-help book 0 2 2
Group course: 8e10 sessions 0 2 2
E-health intervention (unsupported) 0 15 15
Mild depression
E-health intervention (supported) 2 2 1.5
Interapy: online psychotherapy, 10 sessions of CBT 2 2 1.5
Individual psychotherapy, primary care, 8 sessions 17 17 12.4
Moderate depression
E-health intervention (supported) 2 2 1.5
Interapy: online psychotherapy, 14 sessions of CBT 2 2 1.5
Individual psychotherapy, primary care, 8 sessions 16 16 12
Severe depression
Individual psychotherapy, outpatient care, 8e24 sessions 18 18 13.5
Antidepressants, 3e6 months via GP 20 20 15
Antidepressants, 3e6 months, with additional psychological support 20 20 15
Combination therapy (medication and psychotherapy) 16 16 12
Recurrent depression
Clinical management with maintenance medication, 12 months 0 2 2
Mindfulness-based PCT: 8 group sessions 0 2 2
Supported self-help PCT: via the Internet 0 10 10
Notes: CBT: cognitive behavioral therapy; GP: general practitioner; PCT: preventive cognitive therapy.
Lokkerbol et al.factors of primary prevention, cure, and relapse
prevention can be considered a system of healthcare
“echelons” along the disease continuum. Each echelon
consists of a mix of interventions.
Each intervention is described by its impact on
health (Cohen’s d), coverage rate (percentage of
population receiving the intervention), adherence
rate (extent to which patients comply with the inter-
vention), and cost (per intervention per patient).
Effects were based on meta-analyses where possible,
and randomized controlled trials or estimates other-
wise (Table 1). Costs were estimated by mapping the
amount of time of healthcare professionals per
intervention multiplied by hourly rates.
The sum of all cost and total health gains were
calculated at the level of the population. Costs were
restricted to direct medical cost (in euro [V] for the
reference year 2009, converted to US$ by using pur-
chasing power parities).39 Unit cost prices were ob-
tained from the Dutch Guideline for Health Economic
Evaluations.16 Health gains are expressed as a reduc-
tion in the disease burden due to depression (i.e., fewer
disability-adjusted life-years [DALYs]).
Assessing health gains. Healthcare interventions
aim to reduce the number of DALYs in the population.
DALY is a measure of disease burden in a population,
taking into account twocomponents ofdiseaseburden:
morbidity and mortality. Morbidity is related to timeAm J Geriatr Psychiatry -:-, - 2013spent in a health state characterized by a lowered
qualityof lifedue todisability.Mortality comes into the
equation when illness is associated with premature
death. Drummond et al.36 presents a description of the
use of DALYs in economic modeling. In DEPMOD,
DALY reductions are achieved in two ways: by pre-
venting people from becoming depressed through
primary prevention and by treating people who have
depression and thereby lowering their disease burden.Cost-Effectiveness Analysis
To allow for parameter uncertainty in costs and
effects, the model randomly draws a value from the
distributions assigned to the parameters and computes
the outcome for that conﬁguration of parameter values.
This procedure is repeated 1,000 times over all param-
eters simultaneously. In each run, the outcomes (costs
and health gains for each scenarios) are computed and
stored in DEPMOD’s memory. Then, following the
methods of Briggs et al.,35 all 1,000 simulated outcomes
are evaluated simultaneously, thus explicitly accounting
for uncertainty in the input parameters.
After generating 1,000 values of costs and DALYs
for the current and alternative healthcare systems,
costs and effects are discounted when the time
horizon exceeds 1 year. Discounting rates (1.5% for
the effects and 4.0% for the costs, per the pertinent5
TEXT BOX 1. DEPMOD’s Assumptions and Their Consequences
Assumption Justiﬁcation Implication
The 1-year incidence is constant at 238,350
cases per year. Prevalence is 588,600
annually in the adult Dutch population of 10
million people.
Data obtained from The Netherlands Mental
Health Survey and Incidence Study,
a population-based, psychiatric
epidemiologic cohort study.15
Prevalence determines the cost and effects.
The ratio incidence/prevalence determines
the relative importance of prevention.
Episode duration is 6 months on average. After Spijker et al.40 Taking episode duration into account affects
health beneﬁts. A shorter duration means
less potential to generate health beneﬁts.
It is possible to have up to ﬁve recurring
episodes of depression. After the ﬁfth
recurrence, a patient is assumed to be
chronically depressed. Recurrence rates of
depressive disorder are 50%, 70%, 80%,
85%, and 90% for the ﬁrst to the ﬁfth
episode.
Relapse rates are higher after a previous
depressive episode
Increasing risk of recurrence results in
patients making heavier demands on the
healthcare system, which emphasizes the
importance of preventing recurrence from
a cost-effectiveness point of view.
Effects are normally distributed. After Briggs et al.35 Uncertainty around the effect parameters is
symmetrical.
Costs are gamma distributed. After Briggs et al.35 Uncertainty around the cost parameters is
skewed to the right.
Costs include only direct medical costs
(in this article).
Production losses are not relevant for retired
people. Direct nonmedical costs are only
a fraction of direct medical costs.
The model’s output is from the perspective of
healthcare providers, not the patient, and
not from parties such as employers.
WTP for averting one DALY is V20,000
($23,755).
WTP for averting one DALY can be as much as
V80,000 ($95,020). A relative low number
of V20,000 ($23,755) was chosen to be
more conservative.
A healthcare system is deemed cost-effective
when the price per one DALY averted is
less than the WTP ceiling of V20,000
($23,755).
Effects of CBT are maintained over at least
1 year after treatment, but effects of
pharmaceutical interventions decline
almost instantly after discontinuation.
Based on analysis after22 Longer lasting prophylactic effects for CBT
than for pharmaceutical interventions
amounts to in increased cost-effectiveness
of CBT relative to antidepressant
medication.
CBT offered during the acute stage of
depression introduces a prophylactic effect.
After Willemse et al.22 The presence of a prophylactic effect makes it
more desirable to treat acute cases of
depression with CBT because it may help to
avoid new onsets of the disorder in the
future.
CBT: cognitive behavioral therapy; DALY: disability-adjusted life-year; WTP: willingness to pay.
Implementing Telemedicineeconomic guideline) are automatically subjected to
further sensitivity analyses. In the next step,
differences in the costs (incremental costs) and
differences in DALYs (incremental effects) across
both scenarios are obtained, and an estimate of the
incremental cost-effectiveness ratio (ICER) is
computed: ICER ¼ (C1 e C0)/(E1 e E0), were C are
costs, E are effects, and subscripts 1 and 0 refer to
the alternative and base case scenarios, respectively.
The ICER is one of the key outcomes of an economic
evaluation.35 Our time horizon was 5 years, but this
could be changed to a minimum of 1 year. Finally,
the return on investment (ROI) of each scenario is
calculated by dividing DALY health gains, conser-
vatively valued at V20,000 ($23,750) per DALY, by
total cost.6In health economic modeling, making assumptions
is inevitable. Whenever assumptions were made, we
used conservative amounts to decrease the risk of
outcomes being overly optimistic. It is important to
understand how the assumptions affect the outcome
of the model. Text Box 1 presents DEPMOD’s main
assumptions, their justiﬁcations, and their possible
impact on the ﬁndings.RESULTS
Alternative A
The ﬁrst comparison (the base case scenario versus
the alternative Scenario A) evaluates the added value ofAm J Geriatr Psychiatry -:-, - 2013
FIGURE 1. Simulation output costs and disability-adjusted life-
year (DALY) averted in the base case scenario
versus Scenario A.
Lokkerbol et al.offering preventive interventions in terms of improve-
ment in the cost-beneﬁt ratio of the healthcare system.
Cost and effects were modeled out over a period of
5 years. We present here the key ﬁndings. First,
a healthcare system with indicated prevention and
relapse prevention costs 5% more than a system with-
out preventive telemedicine. Second, health gains are
27% higher in the scenario with preventive e-health.
Third, in an evidence-based and preference-based
system without preventive e-health, a mean (standard
deviation [SD]) amount of V13,775 [V724] ($16,361
[$860]) is required for averting one DALY of disease
burden. However, the costs per averted DALY drop to
a more favorableV11,361 [V534] ($13,494 [$634]) when
e-health is offered. Thismeans that the costs for averting
one DALY decline strongly as a result of web-based
prevention, illustrating that the healthcare system in
its entirety becomes more cost-effective, even though
costs increase due to additional investments in pre-
ventive telemedicine. Finally, when averting one DALY
is economically valued at V20,000 ($23,755), the ROI in
the base scenario (without prevention) amounts to
V1.45 [V0.08] per euro invested in healthcare ($1.72
[$0.09] per dollar invested). The ROI improves when
prevention is added (alternative A) to the system and
becomes V1.76 [V0.08] ($2.09 [$0.10]).
In sum, the data suggest that offering preventive
telemedicine makes the healthcare system moreAm J Geriatr Psychiatry -:-, - 2013cost-effective, even though offering preventive tele-
medicine introduces costs of its own. This ﬁnding is
robust because it is hardly affected by uncertainty in
the cost and effect parameters. This can be seen in
Figure 1, in which alternative A is achieved by shifting
the base case scenario to the right (increased DALY
gain), while only slightly shifting the base case
scenario upward (increased cost).
Alternative B
The next scenario introduces the same increase in
preventive telemedicine but decreases the coverage
of (curative) interventions offered in the base scenario
by 25% to keep the total cost of the healthcare system
balanced. Again, the alternative scenario is compared
with the base case scenario and is modeled out over
a period of 5 years. Findings are as before, yet slightly
more favorable. First, because of the decreased
treatment costs in the alternative scenario with 5%,
total costs do not change. Second, due to the relative
cost-effectiveness of preventive e-health, health gains
increase by 23%. Third, as before, it costs (mean [SD])
V13,775 [V724] ($16,361 [$860]) to reduce the disease
burden of depression by one DALY in an evidence-
based and preference-based system without preven-
tive e-health. Under the alternative Scenario B, this
amount becomes V11,279 [V529] ($13,397 [$628]) per
averted DALY. Finally, following the same line of
reasoning, the ROI increases from V1.45 [V0.08]
($1.72 [$0.09]) in the base case scenario to a higher
value of V1.77 [V0.08] ($2.10 [$0.10]) in alternative B.
The corollary is that offering preventive e-health
interventions makes the healthcare system more cost-
effective because a larger health gain is achieved
while keeping costs equal. Figure 2 demonstrates that
the DALY gains in Scenario B are higher, while costs in
both scenarios are comparable. These ﬁndings seem to
be robust as they are unaffected by uncertainty in the
model (as noted by the nonoverlapping uncertainty
intervals in Figure 2).CONCLUSIONS
Main Findings
The main ﬁnding of the current study was that
e-health interventions which seek to prevent onset of
ﬁrst and later episodes of depression can help to7
FIGURE 2. Simulation output costs and disability-adjusted life-
year (DALY) averted in the base case scenario
versus Scenario B.
Implementing Telemedicinemake the healthcare system for depressed patients
more cost-effective overall. Thus, a healthcare system
for depressive disorders that is both evidence based
and preference based (i.e., evidence-based interven-
tions that are met with approval of both healthcare
users and healthcare providers) represents a good
ROI. Modeled out over a period of 5 years, every
euro (dollar) spent would generate health gains
worth V1.45 ($1.72), assuming that averting one
DALY is conservatively valued at V20,000 ($23,755).
However, the same healthcare system with realistic
levels of preventive telemedicine implemented, and
fewer curative interventions, would produce an even
better payout of V1.77 ($2.10) of health-related value
for every euro (dollar) invested.
Although the model is based on a population aged
18e65 years, we believe comparable results are likely to
be obtained for older populations. Evidence suggests
that offering telemedicine to older people is promising.
In a review on telecare for elderly people with chronic
diseases, patients were generally satisﬁed, accepted the
technology, and enjoyed self-monitoring.41 In addition,
evidence speciﬁcally on treating depression in older
people with telemedicine is promising. E-health inter-
ventions proved to be effective in treating depressive
symptoms in older people,19,42 and in a sample of
mainly older people, telemedicinewas successfully used
to adapt a collaborative care model for depression.43 In8addition, from a demographic perspective, the current
generation represented by our data are the elderly of the
future. We may have to substantially rely on health
technologies in the future that are less labor intensive
than our current healthcare models.Strengths and Limitations
One of the beneﬁts of a simulation model is that it
helps to organize vast ﬁelds of knowledge across
several disciplines. In the case of DEPMOD, these
disciplines encompass psychiatric epidemiology and
health economics, while the evidence that supports
effect parameters is drawn from randomized clinical
trials, meta-analyses, and evidence-based clinical
guidelines. It also proved possible to elicit patients’
preferences for certain interventions and to incorpo-
rate these preferences into the model. The model
makes all information available in a dynamic form,
which makes it possible to conduct “if-then” anal-
yses. This could be of assistance when exploring
options for healthcare policies.
Our study has a number of limitations that need to
be acknowledged. In health economic modeling,
much depends on the assumptionsmade in themodel.
Whenever we had to make an assumption, we tried to
make a conservative one; that is, an assumption that is
likely to portray a not overly optimistic outcome
scenario. For example, we used the more conservative
value ofV20,000 ($23,755) for averting one DALY and
not the more generous value of V50,000 ($59,388),
which is frequently suggested in the literature.
Although we accounted for parameter uncertainty to
some extent by using extensive sensitivity analyses,
we emphasize that the value of our model lies in the
comparative analysis of different healthcare scenarios
rather than the interpretation of absolute values.
Another limitation is that the model is based on
a population aged 18e65 years. Data available on the
population older than 65 years are relatively scant,
although evidence seems to suggest that the older
population is willing to use and is receptive to tele-
medicine interventions in general and depression-
oriented telemedicine in particular.19,41e43 We
recommend increasing this knowledge base to assess
the full impact of preventive telemedicine in this age
group, as the older population segment is becoming
increasingly important in terms of healthcare demand
and corresponding costs. Although ourmodel is basedAm J Geriatr Psychiatry -:-, - 2013
Lokkerbol et al.on Dutch data, DEPMOD can be used in other coun-
tries as well. With the appropriate data on epidemi-
ology, effectiveness of interventions, and costs,
DEPMOD could be adapted to different contexts and
population segments. Thus, diverse populations could
be investigated by running DEPMOD separately for
each population segment.
It should also be noted that implementing telemed-
icine on a large scale entails costs of its own. DEPMOD
did not include the costs of making such a transition
from one healthcare system to another. However,
the model did compare the beneﬁt-to-cost ratios of
two healthcare systems after full implementation
(i.e., when the systems were in a steady-state balance).
It is worth noting that implementation, especially in
the presence of a culturally diverse population, is
challenging in its own right.
For these reasons, DEPMOD is best seen as an
explorative decision support tool. It is able to give
almost instant feedback on policy makers’ attempts
to select the economically more attractive scenario in
the context of constrained decision making under
uncertainty in a complex environment. We recom-
mend that DEPMOD be used in an iterative
consensus-building process that encompasses all
pertinent stakeholders (eg, healthcare users, health-
care providers, policy makers). In any case, we would
advise against using DEPMOD as an autopilot for
policy making.
DEPMOD can also be used for setting research
agendas because it helps to identify those parametersAm J Geriatr Psychiatry -:-, - 2013that have an impact on health gains and costs. If any
of these parameters is surrounded by a nontrivial
amount of uncertainty, it is recommended to con-
duct empirical research with the aim of reducing
uncertainty in that parameter. Finally, we wish to
emphasize that ante hoc modeling requires empirical
validation later. It is thus recommended that studies
be conducted to test the hypotheses suggested by the
modeling study.
Implications
Our modeling work shows that preventive inter-
ventions, and especially preventive e-health inter-
ventions, have the potential to improve the
cost-effectiveness of the healthcare system. This
ﬁnding is consistent with other modeling studies
on prevention12,44 and e-health.45 Given the rising
demand for healthcare and the corresponding increase
in healthcare expenditure, preventive telemedicine
could play an important role, especially in graying
societies in which access to the Internet is available to
almost all citizens.
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